Scientific Advisors

Dr. Kowey is a graduate of St Joseph’s University and the University of Pennsylvania School of Medicine. He completed his residency training in internal medicine at Penn State University and was a fellow in cardiovascular medicine and research at the Harvard University School of Public Health, the Peter Bent Brigham Hospital, and the West Roxbury VA Hospital.

Dr. Kowey joined the faculty at the Medical College of Pennsylvania as Director of the CCU and Arrhythmia Program and rose to the rank of full Professor. He went on to become Chief of the Division of Cardiovascular Diseases at the Lankenau Hospital Main Line Health System and President of the Main Line Health Heart Center and is the William Wikoff Smith Chair in Cardiovascular Research. He also is Professor of Medicine and Clinical Pharmacology at Jefferson Medical College.

Dr. Kowey is a fellow of several professional organizations and was a founding member of the Philadelphia Arrhythmia Group and a charter member of the North American Society of Pacing and Electrophysiology. He has served on numerous committees for each of these organizations including program and abstract review committees for national and international programs. He spent 9 years as a member of the Cardiorenal Drug Advisory Committee, 4 years on the Cardiovascular Devices Committee of the Food and Drug Administration and was on the Expert Advisory Panel of the US Pharmacopeial Convention.

Dr. Kowey’s principal area of interest has been cardiac rhythm disturbances. He has been the recipient of over 150 grants and has authored or co-authored over 400 papers and scientific reports. His group has participated in a large number of pivotal clinical trials, many directed by Dr. Kowey himself. He is the Co-editor of 3 textbooks regarding cardiac arrhythmia. He is a referee for manuscript review for 25 journals and sits on the editorial boards of the Heart Rhythm Journal and the Journal of Cardiovascular Electrophysiology. He has provided consultation to over 60 international pharmaceutical companies and chaired several data and safety monitoring boards for clinical trials.

While working with industry, he has pioneered the development of many antiarrhythmic drugs and antitachycardia devices that are used around the world for the treatment of patients with life-threatening cardiac rhythm problems.